Evidence map›Paper›PMID 29905907›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2019

Andrea Farolfi, Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Giambattista Siepe, Alessandro Lambertini, Riccardo Schiavina, Filippo Lodi, Alessio G Morganti, Stefano Fanti

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. [European journal of nuclear medicine and molecular imaging · 2021
    Trial
  5. Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
    Trial
  6. Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Trial
  7. European journal of nuclear medicine and molecular imaging · 2019
    Trial
  8. Article
  9. [International journal of urology : official journal of the Japanese Urological Association · 2026
    Article
  10. Article
  11. Review
  12. PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life.European journal of nuclear medicine and molecular imaging · 2025
    Article
  13. Controversies in the use of next-generation imaging for evaluation and treatment decision-making in patients with prostate cancer after biochemical recurrence: views from a Spanish expert panel.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  14. Superiority ofAnnals of nuclear medicine · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  20. Comparison of digital and analog [Scientific reports · 2024
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea FarolfiMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Francesco CeciMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. francesco.ceci3@unibo.it.ORCID http://orcid.org/0000-0001-9785-5248
Paolo CastellucciMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Tiziano GrazianiMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Giambattista SiepeService of Radiotherapy, Department of Oncology and Hematology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Alessandro LambertiniMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Riccardo SchiavinaDepartment of Urology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Filippo LodiMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Alessio G MorgantiService of Radiotherapy, Department of Oncology and Hematology, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Stefano FantiMetropolitan Nuclear Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe primary aim of this retrospective, single-centre analysis was to assess the performance of

methods

resultsWe enrolled 119 PCa patients (mean age 66 years, range 44-78 years) with a mean PSA level at the time of

conclusionIn our patient series with PSA levels <0.5 ng/ml,

Indexed as

OligopeptidesPositron Emission Tomography Computed TomographyProstatectomyAdultAgedEdetic AcidGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedProstate-Specific AntigenProstatic NeoplasmsRecurrenceRetrospective StudiesSalvage TherapyEdetic Acidgallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesProstate-Specific AntigenBiochemical recurrencePositron emission tomography (PET)Prostate cancerPSMASalvage therapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.